CARE: A Canadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Summary

Client: IQVIA Solutions Canada Inc.

Project ID: P2024-226/ 2026 0980 009 000

Research Question/Objectives: Psoriasis (PsO) is chronic, immune-mediated, inflammatory skin condition, characterized for red scaly plaques and pruritus, affecting an estimated 125 million people worldwide. In Canada, PsO affects approximately 2-3% of the Canadian population. Plaque PsO is the most prevalent clinical variant and accounts for 85-90% of cases.

In addition to the cosmetic or physical impacts, PsO also negatively impacts patient health-related quality of life, emotional and psychological well-being, comorbidity and mortality risk, and leads to social stigmatization and sexual impairment. PsO patients have reported a 17.9% impairment in work productivity and 23.2% to 26.5% in total activity impairment (regular daily activity other than work). Despite major efforts invested in improving PsO diagnosis and treatment, the prevalence, incidence, and the burden caused by this debilitating condition has been rising globally for the past 17 years.
The real-world evidence of the potential impact of brodalumab on plaque PsO patients’ healthcare resource utilization (HCRU) amongst Canadians has not yet been fully demonstrated. This study will provide a description of the HCRU of adults with moderate to severe plaque PsO treated with brodalumab in Ontario over a 12-month period.

Objectives:

Primary Objective:

1. To compare plaque PsO-related HCRU and costs of Ontario patients treated with brodalumab in the CARE study with that of a matched cohort of plaque PsO patients treated with other biologic therapies as captured in Ontario health administrative data at ICES over a 12-month period.

Secondary Objective:

1. To describe plaque PsO-related HCRU and costs of Ontario patients treated with brodalumab in the CARE study as captured in Ontario health administrative data at ICES over a 12-month period.
2. To compare plaque PsO-related HCRU self-reported by Ontario patients treated with brodalumab in the CARE study with plaque PsO-related HCRU captured in Ontario health
   administrative data at ICES over a 12- month period.

Exploratory Objective:

1. To describe plaque PsO-related HCRU and costs of plaque PsO patients treated with other biologic therapies by type as captured in Ontario health administrative data at ICES over a 12 month period.

Status: In progress